Health Care • Medical/Dental Instruments
$149.68 ▼ -2.82
(-1.85%)
MKT CAP: $10.38B • VOL: 1.09M
52W L $126 52W H $355
PODD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.71B | $2.07B | $1.70B |
| YoY Revenue Growth % | +30.7% | +22.1% | — |
| Gross Profit | $1.94B | $1.45B | — |
| Gross Margin % | 71.6% | 69.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $473.8M | $308.9M | $220.1M |
| Operating Margin % | 17.5% | 14.9% | 13.0% |
| Net Income (GAAP) | $247.1M | $418.3M | $206.3M |
| EBITDA (Normalized) | $627.1M | $408.8M | $281.2M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $569.3M | $430.2M | $145.7M |
| Capital Expenditures (CapEx) | $191.6M | $124.9M | $76.4M |
| Free Cash Flow (FCF) | $377.7M | $305.3M | $69.3M |
| FCF Margin % | 13.9% | 14.7% | 4.1% |
| Return on Invested Capital (ROIC %) | 19.5% | 14.2% | 4.9% |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | $753.8M | $844.2M | $1.36B |
| Total Stockholders' Equity | $1.52B | $1.21B | $2.79B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PODD.